BioSpace News Archive

Xcelerate, Inc. (OTCQB:XCRT) today reported its audited financial results for the year ended December 31, 2023. The Company’s Annual Report on Form 1-K has been filed with the U.S. Securities and Exchange Commission.

BostonGene and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, announced today the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based biomarkers.

Discovery Therapeutics Caribe (DTC), a clinical-stage biotechnology company dedicated to improving the health outcomes of Americans through the development of regenerative therapies for serious and life-threatening diseases, today announced it has achieved a significant milestone reflecting progress in its clinical program.

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS

LivaNova PLC, a market-leading medical technology company, announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.

Global “Plasma Fractionation Market” in terms of revenue was estimated to be worth $4.2 Bn in 2023 and is poised to reach $8.9 Bn by 2031, propelling at a CAGR of 10.1% from 2024 to 2031.

According to a new report by Nova One Advisor, the “U.S. AI In Oncology Market” in terms of revenue was estimated to be worth USD 891.90 million in 2023 and is poised to reach USD 10,745.55 million by 2033, growing at a CAGR of 28.26% from 2024 to 2033.

Mythic Therapeutics today announced the publication of preclinical data highlighting the differentiating properties of its investigational cMET-targeting ADC, MYTX-011, in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR).

According to recent study by nova one advisor, the U.S. tissue diagnostics market size was exhibited at USD 2.46 billion in 2023 and is projected to hit around USD 3.61 billion by 2033, growing at a CAGR of 3.92 % during the forecast period 2024 to 2033.

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that’s its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.